NYSE · SYK
Stryker Corporation
Healthcare · Medical - Devices
$273.03▼ 0.86% ($2.36)at close
After hours$273.39▲ 0.13%7:57 PM ET
Market cap
Valuation
Cash-flow DCF
Verdict: fairly priced. Price between Bear and Base.
The price needs 4.9% free cash flow growth a year for 5 years. Our scenarios assume −2.1–25.0%.
That's below its past 10-year pace of 12.9%.
Value per share
Base case
$396.14
Price used $273.03 is 31% below this
USD · TTM ending Jun 30, 2026 · Price Oct 1, 7:59 PM UTC
Interest expense not reported — cost of debt may be understated.
Free cash flow each value needs
Free cash flow today $5.1B. The price needs $9.1B by 2036. Base case: $13.2B. At its recent pace: $17.2B. Bear to Bull: $5.5B to $29.6B.
Free cash flow today $5.1B. The price needs $9.1B by 2036. Base case: $13.2B. At its recent pace: $17.2B. Bear to Bull: $5.5B to $29.6B.
Free cash flow in 2036
today $5.1B
−$4.1Bless than the Base case
Value per share · Base case
$396.14
Price $273.03
31% below this
- Stage 1 growth, yrs 1–5
- 12.9%
- Stage 2 growth, yrs 6–10
- 7.1%
- Discount rate
- 8.6%
Interest expense not reported — cost of debt may be understated.
USD · TTM ending Jun 30, 2026 · Price Oct 1, 7:59 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 25.04% over the last year. Revenue grew 8.48% over the trailing twelve months. Operating margin moved from 22.72% to 22.03%. Free cash flow grew 16.85% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 0th percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.
What would invalidate this read
This read changes if operating margin (currently 22.03%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions.
Market multiples
Stock splits
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 2 shares became 3
Every 1 shares became 2
Every 2 shares became 3
Every 2 shares became 3
Profitability & growth
Analyst consensus
37
Buy
15
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Oct 29, 2026
Q3 FY26 · EPS est $3.56 · Revenue est $6.64B
View
Institutional Sentiment
Stryker Corporation · SYK
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.